Gilead Sciences GILD Total Other — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's total other — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's total other — total revenues?
- Gilead Sciences (GILD) reported total other — total revenues of $196M in Q1 2026.
- How has Gilead Sciences's total other — total revenues changed year-over-year?
- Gilead Sciences's total other — total revenues decreased by 6.2% year-over-year, from $209M to $196M.
- What is the long-term trend for Gilead Sciences's total other — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's total other — total revenues has grown at a -6.1% compound annual growth rate (CAGR), from $1.03B to $800M.
- What does total other — total revenues mean?
- This metric represents the aggregate revenue generated from secondary product lines or miscellaneous therapeutic offerings that fall outside the company's primary core business segments. It captures the financial contribution of smaller, niche, or legacy assets that do not meet the threshold for individual reporting. Monitoring this segment helps investors assess the performance of the company's long-tail portfolio and its ability to monetize non-core therapeutic assets.